Distributions of genotype and allele frequencies of the–308G®A TNF gene polymorphism are shown in Ta­ble 1. We have found a slightly increased TNF*GG geno­type frequency among hematological malignancy patients, but differences among analyzed groups were not signifi­cant (c2  = 0.38, p = 0.54). When the hematological ma­lignancies group were divided according to diagnosis, patients with ALL showed the same distribution of geno­types as the control group. We noted an increased fre­quency of the TNF*AA genotype among AML patients. The TNF*GG genotype frequency in the group of patient with NHL was the highest among the analyzed groups (c2   = 8.15, p = 0.005). The lowest frequency of the TNF*A allele was among NHL patients.

The distribution of genotype and allele frequencies of the +252A®G LTA gene polymorphism among the hema­tological malignancy patients were similar to those ob­served in healthy controls (Table 2). But we did note some increase of the LTA*GG genotype among hematological malignancy patients (c2  = 1.54, p = .22). The LTA*AG genotype frequency was highest in the AML group of patients, and among patients with NHL, the LTA*AA genotype frequency was significantly higher (c2  = 9.12, p = 0.003).

The genotype combinations of the TNF/LTA genes are shown in Table 3. It is important to note that the frequency of the TNF/LTA genotype combinations with at least one mutant allele among AML patients was found in 80% of cases, more often than in any other group. Combinations with one or two mutant alleles in the NHL group were found in only 22.22%, furthermore, we have not found genotype combinations that included more than two mu­tant alleles in the NHL group.